COL11A1 in FAP polyps and in sporadic colorectal tumors -: art. no. 17

COL11A1 in FAP polyps and in sporadic colorectal tumors -: art. no. 17
复制标题

DOI:
10.1186/1471-2407-1-17
复制
发表时间:
2001-01-01
期刊:
影响因子:
3.8
通讯作者:
Lindblom, A
Lindblom, A
中科院分区:
医学2区
文献类型:
--
作者:
Fischer, H;Salahshor, S;Lindblom, A

文献摘要

被引文献

相似文献

背景:我们之前报道过,在大多数散发性结直肠癌中,在结肠中不正常表达的11型胶原α -1链(COL11A1)在间质成纤维细胞中上调。APC基因发生种系突变的患者,除结肠息肉病外,还表现出间质成纤维细胞受损伤的症状,这可能与COL11A1的表达有关。大多数结直肠癌被认为是wnt通路激活的结果,最常涉及APC基因失活或β -连环蛋白激活。方法:我们利用1例FAP患者和37例散发性结直肠癌的正常和息肉组织样本,研究COL11A1的上调是否与APC/ β -catenin通路的活性相关。结果:在本研究中,我们发现一名FAP患者的正常组织和腺瘤中COL11A1的表达有统计学差异,所有腺瘤都表明APC/ β -catenin通路活跃。一个活跃的Wnt通路被认为与WISP-1的基质表达有关。我们发现散发性癌中WISP-1和COL11A1的表达有很强的相关性。结论:COL11A1在结直肠肿瘤中的表达可能与FAP和散发性结直肠癌的APC/ β -catenin通路有关。
Background: We previously reported that the alpha-1 chain of type 11 collagen (COL11A1), not normally expressed in the colon, was up-regulated in stromal fibroblasts in most sporadic colorectal carcinomas. Patients with germline mutations in the APC gene show, besides colonic polyposis, symptoms of stromal fibroblast involvement, which could be related to COL11A1 expression. Most colorectal carcinomas are suggested to be a result of an activated Wnt-pathway, most often involving an inactivation of the APC gene or activation of beta-catenin.Methods: We used normal and polyp tissue samples from one FAP patient and a set of 37 sporadic colorectal carcinomas to find out if the up-regulation of COL11A1 was associated with an active APC/beta-catenin pathway.Results: In this study we found a statistically significant difference in COL11A1 expression between normal tissue and adenomas from one FAP patient, and all adenomas gave evidence for an active APC/beta-catenin pathway. An active Wnt pathway has been suggested to involve stromal expression of WISP-1. We found a strong correlation between WISP-1 and COL11A1 expression in sporadic carcinomas.Conclusions: Our results suggest that expression of COL11A1 in colorectal tumors could be associated with the APC/beta-catenin pathway in FAP and sporadic colorectal cancer.